ValiRx Plc, an investment holding company, engages in the research and development of technologies and products in oncology therapeutics and diagnostics in the United Kingdom. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of rebellious genes, which cause cancers, inflammatory conditions, and Alzheimer’s and autoimmune diseases. The company’s lead drug candidates in late stage pre-clinical development include VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that inhibits the process of apoptosis; and VAL201, a novel peptide for the treatment of hormone refractory prostate cancer, and other indications of hormone induced unregulated growth, including endometriosis. It is also developing ValiFinn BioMarkers that are diagnostic markers of inhibition of signaling pathways, which are target sites for novel drugs to treat cancer; and predictive markers of disease progression, as well as VAL401, a clinical drug to treat patients with lung cancer. The company was incorporated in 2000 and is based in London, the United Kingdom.
valirx plc (VAL:London)
16 Upper Woburn Place
London, WC1H 0BS
Phone: 44 20 3008 4416
Fax: 44 20 3008 4415www.valirx.com
|No competitor information is available for VAL.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.